Created at Source Raw Value Validated value
June 25, 2024, noon usa

inclusion criteria: * adults age 18 or older * tested positive for sars-cov-2 by rt-pcr assay using a respiratory tract sample (either nasopharyngeal swab or oropharyngeal swab or nasal aspirate or tracheobronchial aspirate or saliva) collected within 72 hours of randomization * stated willingness to give their written informed consent to participate in the study * stated willingness to comply with all study procedures and availability for the duration of the study * males must be sterile, or agree not to donate semen and agree to strictly adhere to contraceptive measures during the study and for 7 days following the last dose of study medication * females must be unable to bear children, or ensure that their male partner is incapable of fathering a child, or, if of childbearing potential will strictly adhere to contraceptive measures during the study and for seven days following the last dose of study medication * females must agree to stop breast-feeding prior to first dose of study drug and through seven days after completing therapy * females must have a negative pregnancy test at screening * ability to take oral medication and be willing to adhere to the favipiravir/placebo regimen * subject has access to a smart phone, tablet, or pc * minimal baseline severity score for covid-19-related symptoms: at least two symptoms with a score of 2 or higher. covid-19-related symptoms (excluding changes in the sense of taste or smell) include: * stuffy or runny nose * sore throat * shortness of breath * cough * lack of energy or tiredness * muscle or body aches * headache * chills or shivering * feeling hot or feverish * nausea * diarrhea * vomiting

inclusion criteria: * adults age 18 or older * tested positive for sars-cov-2 by rt-pcr assay using a respiratory tract sample (either nasopharyngeal swab or oropharyngeal swab or nasal aspirate or tracheobronchial aspirate or saliva) collected within 72 hours of randomization * stated willingness to give their written informed consent to participate in the study * stated willingness to comply with all study procedures and availability for the duration of the study * males must be sterile, or agree not to donate semen and agree to strictly adhere to contraceptive measures during the study and for 7 days following the last dose of study medication * females must be unable to bear children, or ensure that their male partner is incapable of fathering a child, or, if of childbearing potential will strictly adhere to contraceptive measures during the study and for seven days following the last dose of study medication * females must agree to stop breast-feeding prior to first dose of study drug and through seven days after completing therapy * females must have a negative pregnancy test at screening * ability to take oral medication and be willing to adhere to the favipiravir/placebo regimen * subject has access to a smart phone, tablet, or pc * minimal baseline severity score for covid-19-related symptoms: at least two symptoms with a score of 2 or higher. covid-19-related symptoms (excluding changes in the sense of taste or smell) include: * stuffy or runny nose * sore throat * shortness of breath * cough * lack of energy or tiredness * muscle or body aches * headache * chills or shivering * feeling hot or feverish * nausea * diarrhea * vomiting

March 4, 2021, 12:31 a.m. usa

inclusion criteria: - adults age 18 or older - tested positive for sars-cov-2 by rt-pcr assay using a respiratory tract sample (either nasopharyngeal swab or oropharyngeal swab or nasal aspirate or tracheobronchial aspirate or saliva) collected within 72 hours of randomization - stated willingness to give their written informed consent to participate in the study - stated willingness to comply with all study procedures and availability for the duration of the study - males must be sterile, or agree not to donate semen and agree to strictly adhere to contraceptive measures during the study and for 7 days following the last dose of study medication - females must be unable to bear children, or ensure that their male partner is incapable of fathering a child, or, if of childbearing potential will strictly adhere to contraceptive measures during the study and for seven days following the last dose of study medication - females must agree to stop breast-feeding prior to first dose of study drug and through seven days after completing therapy - females must have a negative pregnancy test at screening - ability to take oral medication and be willing to adhere to the favipiravir/placebo regimen - subject has access to a smart phone, tablet, or pc - minimal baseline severity score for covid-19-related symptoms: at least two symptoms with a score of 2 or higher. covid-19-related symptoms (excluding changes in the sense of taste or smell) include: - stuffy or runny nose - sore throat - shortness of breath - cough - lack of energy or tiredness - muscle or body aches - headache - chills or shivering - feeling hot or feverish - nausea - diarrhea - vomiting

inclusion criteria: - adults age 18 or older - tested positive for sars-cov-2 by rt-pcr assay using a respiratory tract sample (either nasopharyngeal swab or oropharyngeal swab or nasal aspirate or tracheobronchial aspirate or saliva) collected within 72 hours of randomization - stated willingness to give their written informed consent to participate in the study - stated willingness to comply with all study procedures and availability for the duration of the study - males must be sterile, or agree not to donate semen and agree to strictly adhere to contraceptive measures during the study and for 7 days following the last dose of study medication - females must be unable to bear children, or ensure that their male partner is incapable of fathering a child, or, if of childbearing potential will strictly adhere to contraceptive measures during the study and for seven days following the last dose of study medication - females must agree to stop breast-feeding prior to first dose of study drug and through seven days after completing therapy - females must have a negative pregnancy test at screening - ability to take oral medication and be willing to adhere to the favipiravir/placebo regimen - subject has access to a smart phone, tablet, or pc - minimal baseline severity score for covid-19-related symptoms: at least two symptoms with a score of 2 or higher. covid-19-related symptoms (excluding changes in the sense of taste or smell) include: - stuffy or runny nose - sore throat - shortness of breath - cough - lack of energy or tiredness - muscle or body aches - headache - chills or shivering - feeling hot or feverish - nausea - diarrhea - vomiting

Oct. 26, 2020, 11:31 p.m. usa

inclusion criteria: - adults age 18 or older - tested positive for sars-cov-2 by rt-pcr assay using a respiratory tract sample (either nasopharyngeal swab or oropharyngeal swab or nasal aspirate or tracheobronchial aspirate or saliva) collected within 72 hours of randomization - stated willingness to give their written informed consent to participate in the study - stated willingness to comply with all study procedures and availability for the duration of the study - males must be sterile, or agree not to donate semen and agree to strictly adhere to contraceptive measures during the study and for 7 days following the last dose of study medication - females must be unable to bear children, or ensure that their male partner is incapable of fathering a child, or, if of childbearing potential will strictly adhere to contraceptive measures during the study and for seven days following the last dose of study medication - females must agree to stop breast-feeding prior to first dose of study drug and through seven days after completing therapy - females must have a negative pregnancy test at screening - ability to take oral medication and be willing to adhere to the favipiravir/placebo regimen - one or more of the following symptoms: 1. fever (temperature ≥ 37.2 °c oral) 2. chills 3. cough 4. shortness of breath or difficulty breathing on exertion 5. malaise 6. muscle pain 7. headache 8. new loss of taste or smell 9. sore throat 10. congestion or runny nose 11. nausea or vomiting 12. diarrhea

inclusion criteria: - adults age 18 or older - tested positive for sars-cov-2 by rt-pcr assay using a respiratory tract sample (either nasopharyngeal swab or oropharyngeal swab or nasal aspirate or tracheobronchial aspirate or saliva) collected within 72 hours of randomization - stated willingness to give their written informed consent to participate in the study - stated willingness to comply with all study procedures and availability for the duration of the study - males must be sterile, or agree not to donate semen and agree to strictly adhere to contraceptive measures during the study and for 7 days following the last dose of study medication - females must be unable to bear children, or ensure that their male partner is incapable of fathering a child, or, if of childbearing potential will strictly adhere to contraceptive measures during the study and for seven days following the last dose of study medication - females must agree to stop breast-feeding prior to first dose of study drug and through seven days after completing therapy - females must have a negative pregnancy test at screening - ability to take oral medication and be willing to adhere to the favipiravir/placebo regimen - one or more of the following symptoms: 1. fever (temperature ≥ 37.2 °c oral) 2. chills 3. cough 4. shortness of breath or difficulty breathing on exertion 5. malaise 6. muscle pain 7. headache 8. new loss of taste or smell 9. sore throat 10. congestion or runny nose 11. nausea or vomiting 12. diarrhea